Emerging research suggest Retatrutide , a dual activator targeting both incretin and GIP , could provide a promising advancement for body management . Early clinical investigations have shown impressive losses in body fat , potentially exceeding existing weight-loss therapies . However , more study is required to completely assess its lasting effec